Cutting-Edge Nanotech

Manipulating brain circuits is crucial for understanding and treating neurological disorders, such as Parkinson’s disease, epilepsy, and depression, by influencing neural signaling and restoring balance in brain activity. Current technologies, such as deep brain stimulation, often require invasive procedures and can lead to unwanted side effects, including tissue damage or poor precision in targeting specific brain regions. Our team focuses on developing magnetic and polymeric nanotechnologies that offer a minimally invasive approach to modulate neuronal signaling. These innovative solutions aim to provide more precise, controlled, and safer methods for influencing brain circuits.

The limited ability of nerves to regenerate after injury is a major challenge in treating neurological disorders and spinal cord injuries. Unlike other tissues in the body, nerves have a slow and often incomplete capacity for regeneration, which can result in long-term disability and loss of function. Enhancing nerve regeneration is critical for improving recovery outcomes in individuals with nerve injuries or degenerative diseases. Our team is dedicated to developing novel technological approaches that promote nerve regeneration in a minimally invasive manner, aiming to provide more effective treatments without the need for extensive surgeries or complex interventions.

Gene editing holds significant promise for treating glioblastoma, a highly aggressive and difficult-to-treat brain tumor, by directly targeting and modifying the genetic material within tumor cells. However, one of the major challenges in using gene editing for glioblastoma treatment is the delivery method, particularly when using viral vectors. While viruses can be engineered to deliver genetic material, they face obstacles such as immune responses, difficulty crossing the blood-brain barrier, and the risk of unintended side effects. To overcome these challenges, our team is developing approaches that mimic natural processes, enabling more efficient and targeted delivery of genes directly into glioblastoma tumors. These methods aim to bypass the blood-brain barrier and ensure that gene therapies are safely and effectively delivered to the affected areas.